Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

ClinicalTrials.gov ID: NCT01412060

Public ClinicalTrials.gov record NCT01412060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.

Study identification

NCT ID
NCT01412060
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Forest Laboratories
Industry
Enrollment
765 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 26, 2011
Primary completion
Sep 2, 2014
Completion
Sep 2, 2014
Last update posted
Jul 5, 2018

2011 – 2014

United States locations

U.S. sites
25
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
Forest Investigative Site 011 Little Rock Arkansas 72211
Forest Investigative Site 018 Cerritos California 90703
Forest Investigative Site 007 Costa Mesa California 92626
Forest Investigative Site 026 Culver City California 90230
Forest Investigative Site 008 Long Beach California 90813
Forest Investigative Site 002 Oceanside California 92056
Forest Investigative Site 019 Orange California 92868
Forest Investigative Site 001 Paramount California 90723
Forest Investigative Site 020 San Diego California 92123
Forest Investigative Site 005 Washington D.C. District of Columbia 20016
Forest Investigative Site 024 Leesburg Florida 34748
Forest Investigative Site 017 Atlanta Georgia 30331
Forest Investigative Site 021 Chicago Illinois 60640
Forest Investigative Site 023 Baltimore Maryland 21202
Forest Investigative Site 010 Rockville Maryland 20850
Forest Investigative Site 003 Flowood Mississippi 39232
Forest Investigative Site 006 Creve Coeur Missouri 63141
Forest Investigative Site 014 St Louis Missouri 63141
Forest Investigative Site 012 Cedarhurst New York 11516
Forest Investigative Site 022 Dayton Ohio 45417
Forest Investigative Site 015 Austin Texas 78731
Forest Investigative Site 027 Austin Texas 78754
Forest Investigative Site 025 Dallas Texas 75231
Forest Investigative Site 013 Houston Texas 77008
Forest Investigative Site 009 Houston Texas 77021

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01412060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 5, 2018 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01412060 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →